The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Development of a guidance for including patient-reported outcomes (PROs) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER).
E. M. Basch
No relevant relationships to disclose
A. P. Abernethy
Consultant or Advisory Role - Amgen; Helsinn Therapeutics; Proventys
Research Funding - Alexion Pharmaceuticals; Amgen; BioVex; Helsinn Therapeutics; Lilly; Pfizer
C. D. Mullins
No relevant relationships to disclose
M. R. Tiglao
No relevant relationships to disclose
S. R. Tunis
No relevant relationships to disclose